Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
18.54
-2.99 (-13.89%)
At close: Jan 29, 2025, 4:00 PM
18.59
+0.05 (0.27%)
After-hours: Jan 29, 2025, 7:52 PM EST
Teva Pharmaceutical Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Teva Pharmaceutical stock have an average target of 23, with a low estimate of 11 and a high estimate of 30. The average target predicts an increase of 24.06% from the current stock price of 18.54.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Teva Pharmaceutical stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $28 → $30 | Strong Buy | Maintains | $28 → $30 | +61.81% | Jan 23, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $23 → $30 | Buy | Maintains | $23 → $30 | +61.81% | Jan 17, 2025 |
| Barclays | Barclays | Buy Maintains $25 → $28 | Buy | Maintains | $25 → $28 | +51.02% | Dec 18, 2024 |
| Barclays | Barclays | Buy Maintains $22 → $25 | Buy | Maintains | $22 → $25 | +34.84% | Oct 23, 2024 |
| JP Morgan | JP Morgan | Hold Maintains $16 → $18 | Hold | Maintains | $16 → $18 | -2.91% | Oct 21, 2024 |
Financial Forecast
Revenue This Year
16.76B
from 15.85B
Increased by 5.74%
Revenue Next Year
17.50B
from 16.76B
Increased by 4.46%
EPS This Year
2.48
from -0.50
EPS Next Year
2.85
from 2.48
Increased by 14.78%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 17.3B | 18.5B | 19.3B |
| Avg | 16.8B | 17.5B | 17.7B |
| Low | 16.0B | 16.2B | 16.0B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 9.2% | 10.7% | 10.2% |
| Avg | 5.7% | 4.5% | 1.2% |
| Low | 1.2% | -3.4% | -8.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 2.60 | 3.26 | 3.16 |
| Avg | 2.48 | 2.85 | 3.00 |
| Low | 2.32 | 2.61 | 2.76 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | 31.1% | 10.9% |
| Avg | - | 14.8% | 5.3% |
| Low | - | 5.0% | -3.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.